Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼Ò¾Æû¼Ò³â ÁøÁ¤³»½Ã°æ: ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ ÇмúÀ§¿øȸ Á¶»ç º¸°í Pediatric Endoscopic Sedation in Korea: A Survey of the Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition

´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸÁö 2008³â 11±Ç 1È£ p.21 ~ 27
·ùÀÏ, ±è°æ¸ð,
¼Ò¼Ó »ó¼¼Á¤º¸
·ùÀÏ ( Ryoo Eell ) 
°¡ÃµÀÇ°úÇдëÇб³ ¼Ò¾Æ°úÇб³½Ç

±è°æ¸ð ( Kim Kyung-Mo ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¾Æ»êº´¿ø ¼Ò¾Æ°ú

Abstract

¸ñ Àû: Çѱ¹ ¼Ò¾Æû¼Ò³â¿¡¼­ ½ÃÇàµÇ´Â ÀǽÄÇÏ ÁøÁ¤³»½Ã°æ ½ÃÇà ½ÇÅÂ¿Í ºÎÀÛ¿ë, ±×¸®°í »õ·Î¿î ¾àÁ¦ µîÀÇ »ç¿ë ¿©ºÎ µîÀ» ´Ù±â°ü ¿¬±¸¸¦ ÅëÇØ ÆľÇÇÏ¿© ÀûÀýÇÑ ÁöħÀ» ¼¼¿ì´Âµ¥ µµ¿òÀ» ÁÖ°íÀÚ ÇÏ¿´´Ù.

¹æ ¹ý: ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ ȸ¿ø ¼Ò¼Ó º´¿ø Áß 2Â÷ º´¿ø ÀÌ»óÀÇ º´¿øÀ» ´ë»óÀ¸·Î 2006³â 6¿ùºÎÅÍ 2006³â 7¿ù±îÁö ÇÑ ´ÞÀÇ ±â°£ µ¿¾È ½ÃÇàµÈ ³»½Ã°æ °Ë»ç¸¦ ´ë»óÀ¸·Î ÇÏ¿´À¸¸ç, 16°³ÀÇ ¹®Ç×À¸·Î ¼³¹®Áö¸¦ ¸¸µé¾î ¹èÆ÷ ÈÄ ¼ö°ÅµÈ °á°ú¸¦ Á¶»ç ºÐ¼®ÇÏ¿´´Ù.

°á °ú: Àüü ³»½Ã°æ ½Ã¼ú Ƚ¼ö 465¿¹ Áß ÀǽÄÇÏ ÁøÁ¤ ³»½Ã°æÀº 89.0% (414¿¹), Àü½Å ¸¶ÃëÇÏ¿¡ ½Ã¼úÇÑ ¿¹´Â 0.9% (4¿¹)¿´À¸¸ç, ÀǽÄÇÏ ÁøÁ¤³»½Ã°æÀÇ ºñÀ²Àº »óºÎ¼ÒÈ­°üÀÇ °æ¿ì 89.1% (362¿¹), ÇϺμÒÈ­°üÀÇ °æ¿ì´Â 88.1% (52¿¹)¿´´Ù. ÀÇ»ç ÇÑ ¸í ´ç ÇÑ´Þ Æò±Õ 16.0°ÇÀÇ ³»½Ã°æÀ» ½Ã¼úÇÏ°í ÀÖ¾úÀ¸¸ç, ³»½Ã°æÀ» ½ÃÇàÇÏ´Â ÀÇ»ç ¼ö´Â º´¿ø´ç Æò±Õ 1.16¸í, º¸Á¶ÀÚ´Â Æò±Õ 2.58¸íÀ̾ú´Ù. ¶ÇÇÑ ¸¶Ãë°ú ÀÇ»çÀÇ µµ¿òÀ» ¹Þ´Â °æ¿ì´Â 3°³(12%) º´¿øÀ̾ú´Ù. »ç¿ëÇÑ ¾à¹°Àº Àüü ÀǽÄÇÏ ÁøÁ¤³»½Ã°æ 414¿¹ Áß ¹Ì´ÙÁ¹¶÷(midazolam)¸¸ »ç¿ëÇÑ °æ¿ì°¡ Àüü 84.5% (350¿¹), ÇÁ·ÎÆ÷Æú(propofol)À» »ç¿ëÇÑ °æ¿ì´Â »óºÎ¼ÒÈ­°ü ³»½Ã°æÀ» ½ÃÇàÇÑ 2¿¹(0.5%)¿´°í, 2°¡Áö ÀÌ»óÀÇ º¹ÇÕÁ¦À縦 »ç¿ëÇÑ °æ¿ì´Â ÇϺμÒÈ­°ü°Ë»çÀÇ °æ¿ì 44¿¹(84.6%), ¿ªÇ༺´ã°üÁ¶¿µ¼ú(ERCP)ÀÇ °æ¿ì°¡ 2¿¹(100%)¿´´Ù. ÁøÁ¤ ³»½Ã°æ ½ÃÇà Áß »ç¿ëÇÑ ¸ð´ÏÅ͸µÀº ½ÉÀüµµ °¨½Ã¿Í ÇÔ²² ¸Æ¹Ú»ê¼ÒÃøÁ¤±â¸¦ »ç¿ëÇÑ °æ¿ì°¡ 91.4% (320¿¹), ÀÚµ¿Ç÷¾ÐÃøÁ¤±â¸¦ °°ÀÌ »ç¿ëÇÑ °æ¿ì 5.1% (18¿¹)¿´´Ù. ºÎÀÛ¿ëÀ¸·Î´Â ÀϽÃÀû »ê¼ÒÆ÷È­µµÀÇ ÀúÇÏ·Î »ê¼Ò¸¦ Åõ¿©ÇÑ °æ¿ì·Î 4.6% (16¿¹)¿´´Ù. ¶ÇÇÑ ±æÇ×Á¦·Î flumazenilÀ» Åõ¿©ÇÑ °æ¿ì´Â ¸ðµç ȯÀÚ¿¡¼­ Åõ¿©ÇÑ´Ù°í ´äÇÑ °æ¿ì¸¦ Á¦¿ÜÇϸé 2.71% (9¿¹)¿´´Ù. ÁøÁ¤³»½Ã°æ ½ÃÇà ¿©ºÎÀÇ °áÁ¤Àº ȯÀÚ È¤Àº ȯÀÚÀÇ º¸È£ÀÚ¿Í »óÀÇÇÏ¿© °áÁ¤ÇÏ´Â °æ¿ì°¡ 84% (21°³ º´¿ø)¿´´Ù. Àǻ簡 ´À³¢´Â ¸¸Á·µµ´Â 68%¿¡¼­ ¸¸Á·ÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µÀ¸¸ç, Àǻ簡 ´À³¢´Â ȯÀÚ È¤Àº ȯÀÚ º¸È£ÀÚÀÇ ¸¸Á·µµ´Â ¸¸Á·ÀÌ 84% (21°³ º´¿ø)¿´´Ù.

°á ·Ð: ¿ì¸®³ª¶ó ¼Ò¾ÆÀÇ ÀǽÄÇÏ ÁøÁ¤³»½Ã°æ ½Ã »ç¿ëÇÑ ¾à¹°Àº ´ëºÎºÐ ¹Ì´ÙÁ¹¶÷ ´Üµ¶ Åõ¿©¸¸À¸·Î ½ÃÇàÇϸç, ÇϺμÒÈ­°ü °Ë»ç ½Ã¿¡´Â º¹ÇÕ ¾à¹°À» Åõ¿©ÇÑ °æ¿ì°¡ ¸¹¾Ò´Ù. ¶ÇÇÑ È¯ÀÚ¿Í ÀÇ»ç ´ëºÎºÐ ¸¸Á·ÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µÀ¸¸ç, ºÎÀÛ¿ëÀº °ÅÀÇ ³ªÅ¸³ªÁö ¾Ê¾Ò´Ù.

Purpose: The aim of this survey was to analyze the choice of sedative drugs and their side effects during pediatric endoscopic sedation in Korea. We also evaluated doctors, caretakers and patient satisfaction with the procedures.

Methods: Between June 2006 and July 2006, a 16-item survey regarding current sedation practices, during one month, was mailed to 28 hospitals in Korea. The results of the survey responses were then analyzed.

Results: Endoscopy performed under conscious sedation was reported in 89.0% of the responders and endoscopy under general anesthesia in 0.9% of 465 endoscopic procedures. Endoscopy under conscious sedation was performed in 89.1% for upper gastrointestinal endoscopy (GFS) and 88.1% for lower GFS. Midazolam was used for conscious sedation during the endoscopy in 84.5% of cases and propofol was used in two cases (0.5%). In addition, a bezodiazepine/opioid combination was used iin 84.6% (44 cases) for lower GFS. Patients were monitored with pulse oxymetry, EKG (91.4%) as well as automatic BP (5.1%). Transient hypoxia was the only side effect noted and was treated with supplemental oxygen (4.6%). Flumazenil was used in 2.71% of cases. The choice of sedation was made by the endoscopist (84%). The satisfaction rate for endoscopists was 68%, and for the patients and caretakers was 84% (as reported by the endoscopists).

Conclusion: Midazolam was used only for the upper GFS and benzodiazepine/opioid combination was used for the lower GFS in Korea. The rate of satisfaction was relatively high and there were no significant side effects noted during the endoscopy under conscious sedation. (Korean J Pediatr Gastroenterol Nutr 2008; 11: 21¡­27)

Å°¿öµå

Pediatric endoscopic sedation;Midazolam;Benzodiazepine/opioid combination

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS